Search Results - "Cloesmeijer, Michael E"

PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space by Cloesmeijer, Michael E., Sjögren, Erik, Koopman, Sjoerd F., Lenting, Peter. J., Cnossen, Marjon H., Mathôt, Ron A. A.

“…Patients with severe and sometimes moderate hemophilia B are prophylactically treated with factor IX concentrates to prevent bleeding. For some time now,…”
Get full text

ChatGPT in pharmacometrics? Potential opportunities and limitations by Cloesmeijer, Michael E., Janssen, Alexander, Koopman, Sjoerd F., Cnossen, Marjon H., Mathôt, Ron A. A.

“…The potential of using ChatGPT in pharmacometrics was explored in this study, with a focus on developing a population pharmacokinetic (PK) model for standard…”
Get full text

Impact of enantiomer‐specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis by Cloesmeijer, Michael E., Esdonk, Michiel J., Lynn, Anne M., Smits, Anne, Tibboel, Dick, Daali, Youssef, Olkkola, Klaus T., Allegaert, Karel, Mian, Paola

“…Aims Ketorolac is a nonsteroidal anti‐inflammatory racemic drug with analgesic effects only attributed to its S‐enantiomer. The aim of this study is to…”
Get full text

Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics by Cloesmeijer, Michael E., Oever, Huub L.A., Mathôt, Ron A.A., Zeeman, Marieke, Kruisdijk‐Gerritsen, Arriette, Bles, Carmen M.A., Nassikovker, Polina, Meijer, Arthur R., Steveninck, Fred L., Arbouw, Maurits E.L.

“…Aims The aim of this study was to investigate the population pharmacokinetics (PK) of clonidine in intensive care unit (ICU) patients in order to develop a…”
Get full text

Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study by Heijdra, Jessica M., Cloesmeijer, Michael E., Jager, Nico C.B., Leebeek, Frank W.G., Kruip, Marieke H.J.A., Cnossen, Marjon H., Mathôt, Ron A.A.

“…Introduction Desmopressin can be used to prevent bleeding in von Willebrand disease (VWD), but the relationship between desmopressin and von Willebrand factor…”
Get full text

Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate by Valke, Lars L. F. G., Cloesmeijer, Michael E., Mansouritorghabeh, Hassan, Barteling, Wideke, Blijlevens, Nicole M. A., Cnossen, Marjon H., Mathôt, Ron A. A., Schols, Saskia E. M., van Heerde, Waander L.

“…Background Hemophilia A patients are treated with factor (F) VIII prophylactically to prevent bleeding. In general, dosage and frequency are based on…”
Get full text

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study by Heijdra, Jessica M, Al Arashi, Wala, de Jager, Nico C B, Cloesmeijer, Michael E, Bukkems, Laura H, Zwaan, Christian M, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Cnossen, MH, Leebeek, FWG, Fijnvandraat, K, Mathôt, RAA, Meijer, K, Kruip, MJHA, Polinder, S, Coppens, M, Tamminga, RYJ, Laros-van Gorkom, BAP, Brons, P, Schols, SEM, van der Meer, FJM, Eikenboom, HCJ, Schutgens, REG, Fischer, K, Heubel-Moenen, F, Nieuwenhuizen, L, Ypma, P, Driessens, MHE, Zwaan, CM, van Vliet, I, Collins, PW, Liesner, R, Chowdary, P, Keeling, D, Lock, J, Hazendonk, HCAM, van Moort, I, Preijers, T, Heijdra, JM, de Jager, NCB, Goedhart, MCHJ, Bukkems, LH, Al Arashi, W, Cloesmeijer, ME, Janssen, A

“…IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures…”
Get full text